nodes	percent_of_prediction	percent_of_DWPC	metapath
Bosutinib—SRC—type 2 diabetes mellitus	0.192	0.522	CbGaD
Bosutinib—EGFR—type 2 diabetes mellitus	0.129	0.35	CbGaD
Bosutinib—CYP3A4—type 2 diabetes mellitus	0.0472	0.128	CbGaD
Bosutinib—ABCB1—Linagliptin—type 2 diabetes mellitus	0.0136	0.133	CbGbCtD
Bosutinib—ABCB1—Sitagliptin—type 2 diabetes mellitus	0.0121	0.118	CbGbCtD
Bosutinib—ABCB1—Chlorpropamide—type 2 diabetes mellitus	0.00874	0.0855	CbGbCtD
Bosutinib—CYP3A4—Linagliptin—type 2 diabetes mellitus	0.00813	0.0795	CbGbCtD
Bosutinib—CYP3A4—Sitagliptin—type 2 diabetes mellitus	0.00724	0.0708	CbGbCtD
Bosutinib—CYP3A4—Glipizide—type 2 diabetes mellitus	0.00662	0.0648	CbGbCtD
Bosutinib—ABCB1—Bromocriptine—type 2 diabetes mellitus	0.006	0.0587	CbGbCtD
Bosutinib—CYP3A4—Repaglinide—type 2 diabetes mellitus	0.00579	0.0566	CbGbCtD
Bosutinib—CYP3A4—Pioglitazone—type 2 diabetes mellitus	0.00524	0.0512	CbGbCtD
Bosutinib—ABCB1—Glyburide—type 2 diabetes mellitus	0.00447	0.0437	CbGbCtD
Bosutinib—ABCB1—Losartan—type 2 diabetes mellitus	0.00409	0.04	CbGbCtD
Bosutinib—CYP3A4—Nateglinide—type 2 diabetes mellitus	0.00397	0.0388	CbGbCtD
Bosutinib—CYP3A4—Orlistat—type 2 diabetes mellitus	0.0038	0.0372	CbGbCtD
Bosutinib—CYP3A4—Irbesartan—type 2 diabetes mellitus	0.0038	0.0372	CbGbCtD
Bosutinib—CYP3A4—Bromocriptine—type 2 diabetes mellitus	0.0036	0.0352	CbGbCtD
Bosutinib—CYP3A4—Glyburide—type 2 diabetes mellitus	0.00268	0.0262	CbGbCtD
Bosutinib—CYP3A4—Losartan—type 2 diabetes mellitus	0.00245	0.024	CbGbCtD
Bosutinib—ERBB3—Bortezomib—Nateglinide—type 2 diabetes mellitus	0.000919	0.52	CbGdCrCtD
Bosutinib—Vandetanib—SRC—type 2 diabetes mellitus	0.000916	0.25	CrCbGaD
Bosutinib—CSK—Bortezomib—Nateglinide—type 2 diabetes mellitus	0.000848	0.48	CbGdCrCtD
Bosutinib—Vandetanib—VEGFA—type 2 diabetes mellitus	0.00073	0.199	CrCbGaD
Bosutinib—Vandetanib—EGFR—type 2 diabetes mellitus	0.000616	0.168	CrCbGaD
Bosutinib—Gefitinib—EGFR—type 2 diabetes mellitus	0.000585	0.16	CrCbGaD
Bosutinib—SIK1—nephron tubule—type 2 diabetes mellitus	0.000324	0.00262	CbGeAlD
Bosutinib—CASK—liver—type 2 diabetes mellitus	0.000323	0.00262	CbGeAlD
Bosutinib—MAP2K1—cardiovascular system—type 2 diabetes mellitus	0.000323	0.00262	CbGeAlD
Bosutinib—NUAK2—pancreas—type 2 diabetes mellitus	0.000323	0.00262	CbGeAlD
Bosutinib—CSK—cardiovascular system—type 2 diabetes mellitus	0.000321	0.0026	CbGeAlD
Bosutinib—EIF2AK1—liver—type 2 diabetes mellitus	0.00032	0.00259	CbGeAlD
Bosutinib—STK3—adipose tissue—type 2 diabetes mellitus	0.00032	0.00259	CbGeAlD
Bosutinib—ERBB4—adipose tissue—type 2 diabetes mellitus	0.00032	0.00259	CbGeAlD
Bosutinib—CSNK1A1—cardiovascular system—type 2 diabetes mellitus	0.000319	0.00258	CbGeAlD
Bosutinib—ERBB3—nephron tubule—type 2 diabetes mellitus	0.000317	0.00257	CbGeAlD
Bosutinib—CLK1—cardiovascular system—type 2 diabetes mellitus	0.000317	0.00257	CbGeAlD
Bosutinib—BCR—cortex of kidney—type 2 diabetes mellitus	0.000316	0.00256	CbGeAlD
Bosutinib—NUAK2—cortex of kidney—type 2 diabetes mellitus	0.000316	0.00256	CbGeAlD
Bosutinib—MAP2K1—kidney—type 2 diabetes mellitus	0.000316	0.00256	CbGeAlD
Bosutinib—RPS6KB1—retina—type 2 diabetes mellitus	0.000315	0.00255	CbGeAlD
Bosutinib—MAP3K2—nephron tubule—type 2 diabetes mellitus	0.000314	0.00255	CbGeAlD
Bosutinib—CSK—kidney—type 2 diabetes mellitus	0.000314	0.00254	CbGeAlD
Bosutinib—STK35—pancreas—type 2 diabetes mellitus	0.000314	0.00254	CbGeAlD
Bosutinib—CSNK1A1—kidney—type 2 diabetes mellitus	0.000312	0.00253	CbGeAlD
Bosutinib—CSK—pancreas—type 2 diabetes mellitus	0.000312	0.00253	CbGeAlD
Bosutinib—AXL—retina—type 2 diabetes mellitus	0.000311	0.00252	CbGeAlD
Bosutinib—CAMK2G—cardiovascular system—type 2 diabetes mellitus	0.000311	0.00252	CbGeAlD
Bosutinib—FES—liver—type 2 diabetes mellitus	0.00031	0.00251	CbGeAlD
Bosutinib—VRK2—liver—type 2 diabetes mellitus	0.00031	0.00251	CbGeAlD
Bosutinib—CLK1—kidney—type 2 diabetes mellitus	0.00031	0.00251	CbGeAlD
Bosutinib—CSNK1A1—pancreas—type 2 diabetes mellitus	0.00031	0.00251	CbGeAlD
Bosutinib—CLK1—pancreas—type 2 diabetes mellitus	0.000308	0.0025	CbGeAlD
Bosutinib—PTK2—nephron tubule—type 2 diabetes mellitus	0.000308	0.0025	CbGeAlD
Bosutinib—TBK1—nephron tubule—type 2 diabetes mellitus	0.000308	0.0025	CbGeAlD
Bosutinib—YES1—islet of Langerhans—type 2 diabetes mellitus	0.000308	0.00249	CbGeAlD
Bosutinib—BMPR2—adipose tissue—type 2 diabetes mellitus	0.000306	0.00248	CbGeAlD
Bosutinib—CSK—cortex of kidney—type 2 diabetes mellitus	0.000306	0.00248	CbGeAlD
Bosutinib—TNIK—liver—type 2 diabetes mellitus	0.000304	0.00246	CbGeAlD
Bosutinib—STK36—adipose tissue—type 2 diabetes mellitus	0.000304	0.00246	CbGeAlD
Bosutinib—CSNK1A1—cortex of kidney—type 2 diabetes mellitus	0.000304	0.00246	CbGeAlD
Bosutinib—TAOK3—islet of Langerhans—type 2 diabetes mellitus	0.000304	0.00246	CbGeAlD
Bosutinib—CAMK2G—pancreas—type 2 diabetes mellitus	0.000302	0.00245	CbGeAlD
Bosutinib—CLK1—cortex of kidney—type 2 diabetes mellitus	0.000302	0.00245	CbGeAlD
Bosutinib—IRAK1—nephron tubule—type 2 diabetes mellitus	0.000302	0.00245	CbGeAlD
Bosutinib—LRRK2—kidney—type 2 diabetes mellitus	0.000302	0.00244	CbGeAlD
Bosutinib—CDK2—liver—type 2 diabetes mellitus	0.000301	0.00244	CbGeAlD
Bosutinib—MERTK—adipose tissue—type 2 diabetes mellitus	0.000301	0.00244	CbGeAlD
Bosutinib—PTK2B—cardiovascular system—type 2 diabetes mellitus	0.0003	0.00243	CbGeAlD
Bosutinib—STK26—liver—type 2 diabetes mellitus	0.000298	0.00242	CbGeAlD
Bosutinib—CAMK2G—cortex of kidney—type 2 diabetes mellitus	0.000296	0.0024	CbGeAlD
Bosutinib—SRC—islet of Langerhans—type 2 diabetes mellitus	0.000296	0.0024	CbGeAlD
Bosutinib—MAP4K4—adipose tissue—type 2 diabetes mellitus	0.000295	0.00239	CbGeAlD
Bosutinib—PTK2B—kidney—type 2 diabetes mellitus	0.000294	0.00238	CbGeAlD
Bosutinib—LRRK2—cortex of kidney—type 2 diabetes mellitus	0.000294	0.00238	CbGeAlD
Bosutinib—BCR—adipose tissue—type 2 diabetes mellitus	0.000293	0.00237	CbGeAlD
Bosutinib—NUAK2—adipose tissue—type 2 diabetes mellitus	0.000293	0.00237	CbGeAlD
Bosutinib—MAP3K12—adipose tissue—type 2 diabetes mellitus	0.000291	0.00236	CbGeAlD
Bosutinib—CSNK1E—pancreas—type 2 diabetes mellitus	0.000287	0.00233	CbGeAlD
Bosutinib—DMPK—liver—type 2 diabetes mellitus	0.000286	0.00232	CbGeAlD
Bosutinib—WEE1—liver—type 2 diabetes mellitus	0.000286	0.00232	CbGeAlD
Bosutinib—MAP2K1—adipose tissue—type 2 diabetes mellitus	0.000285	0.00231	CbGeAlD
Bosutinib—STK35—adipose tissue—type 2 diabetes mellitus	0.000285	0.00231	CbGeAlD
Bosutinib—SIK1—kidney—type 2 diabetes mellitus	0.000285	0.00231	CbGeAlD
Bosutinib—MAP2K2—cardiovascular system—type 2 diabetes mellitus	0.000284	0.00231	CbGeAlD
Bosutinib—CSK—adipose tissue—type 2 diabetes mellitus	0.000283	0.00229	CbGeAlD
Bosutinib—SIK1—pancreas—type 2 diabetes mellitus	0.000283	0.00229	CbGeAlD
Bosutinib—SLK—nephron tubule—type 2 diabetes mellitus	0.000282	0.00229	CbGeAlD
Bosutinib—CSNK1E—cortex of kidney—type 2 diabetes mellitus	0.000282	0.00228	CbGeAlD
Bosutinib—CSNK1A1—adipose tissue—type 2 diabetes mellitus	0.000281	0.00228	CbGeAlD
Bosutinib—EPHB4—nephron tubule—type 2 diabetes mellitus	0.00028	0.00227	CbGeAlD
Bosutinib—CLK1—adipose tissue—type 2 diabetes mellitus	0.000279	0.00226	CbGeAlD
Bosutinib—HCK—adipose tissue—type 2 diabetes mellitus	0.000279	0.00226	CbGeAlD
Bosutinib—ERBB3—kidney—type 2 diabetes mellitus	0.000279	0.00226	CbGeAlD
Bosutinib—MAP2K2—kidney—type 2 diabetes mellitus	0.000278	0.00226	CbGeAlD
Bosutinib—ABL2—adipose tissue—type 2 diabetes mellitus	0.000278	0.00225	CbGeAlD
Bosutinib—SIK1—cortex of kidney—type 2 diabetes mellitus	0.000277	0.00225	CbGeAlD
Bosutinib—ERBB3—pancreas—type 2 diabetes mellitus	0.000277	0.00225	CbGeAlD
Bosutinib—TBK1—cardiovascular system—type 2 diabetes mellitus	0.000277	0.00224	CbGeAlD
Bosutinib—PTK2—cardiovascular system—type 2 diabetes mellitus	0.000277	0.00224	CbGeAlD
Bosutinib—MAP2K2—pancreas—type 2 diabetes mellitus	0.000276	0.00224	CbGeAlD
Bosutinib—EPHA2—nephron tubule—type 2 diabetes mellitus	0.000275	0.00223	CbGeAlD
Bosutinib—FYN—nephron tubule—type 2 diabetes mellitus	0.000274	0.00222	CbGeAlD
Bosutinib—BMP2K—adipose tissue—type 2 diabetes mellitus	0.000274	0.00222	CbGeAlD
Bosutinib—CAMK2G—adipose tissue—type 2 diabetes mellitus	0.000274	0.00222	CbGeAlD
Bosutinib—STK25—liver—type 2 diabetes mellitus	0.000273	0.00221	CbGeAlD
Bosutinib—LRRK2—adipose tissue—type 2 diabetes mellitus	0.000272	0.0022	CbGeAlD
Bosutinib—MAP2K2—cortex of kidney—type 2 diabetes mellitus	0.000271	0.0022	CbGeAlD
Bosutinib—ULK3—cortex of kidney—type 2 diabetes mellitus	0.000271	0.0022	CbGeAlD
Bosutinib—EGFR—adipose tissue—type 2 diabetes mellitus	0.000271	0.0022	CbGeAlD
Bosutinib—PTK2—kidney—type 2 diabetes mellitus	0.000271	0.00219	CbGeAlD
Bosutinib—TBK1—kidney—type 2 diabetes mellitus	0.000271	0.00219	CbGeAlD
Bosutinib—TBK1—pancreas—type 2 diabetes mellitus	0.000269	0.00218	CbGeAlD
Bosutinib—PTK2—pancreas—type 2 diabetes mellitus	0.000269	0.00218	CbGeAlD
Bosutinib—MAP3K3—nephron tubule—type 2 diabetes mellitus	0.000268	0.00217	CbGeAlD
Bosutinib—MAP3K7—cortex of kidney—type 2 diabetes mellitus	0.000267	0.00216	CbGeAlD
Bosutinib—RPS6KB1—cardiovascular system—type 2 diabetes mellitus	0.000266	0.00216	CbGeAlD
Bosutinib—PLK2—liver—type 2 diabetes mellitus	0.000265	0.00215	CbGeAlD
Bosutinib—PTK2B—adipose tissue—type 2 diabetes mellitus	0.000265	0.00215	CbGeAlD
Bosutinib—FGR—cardiovascular system—type 2 diabetes mellitus	0.000264	0.00214	CbGeAlD
Bosutinib—SIK3—liver—type 2 diabetes mellitus	0.000264	0.00214	CbGeAlD
Bosutinib—PTK2—cortex of kidney—type 2 diabetes mellitus	0.000264	0.00214	CbGeAlD
Bosutinib—TBK1—cortex of kidney—type 2 diabetes mellitus	0.000264	0.00214	CbGeAlD
Bosutinib—IRAK1—pancreas—type 2 diabetes mellitus	0.000264	0.00214	CbGeAlD
Bosutinib—AXL—cardiovascular system—type 2 diabetes mellitus	0.000263	0.00213	CbGeAlD
Bosutinib—YES1—retina—type 2 diabetes mellitus	0.000263	0.00213	CbGeAlD
Bosutinib—CSNK1E—adipose tissue—type 2 diabetes mellitus	0.000261	0.00211	CbGeAlD
Bosutinib—RPS6KB1—kidney—type 2 diabetes mellitus	0.00026	0.00211	CbGeAlD
Bosutinib—TAOK3—retina—type 2 diabetes mellitus	0.00026	0.0021	CbGeAlD
Bosutinib—RPS6KB1—pancreas—type 2 diabetes mellitus	0.000259	0.0021	CbGeAlD
Bosutinib—IRAK1—cortex of kidney—type 2 diabetes mellitus	0.000258	0.00209	CbGeAlD
Bosutinib—SIK1—adipose tissue—type 2 diabetes mellitus	0.000257	0.00208	CbGeAlD
Bosutinib—IRAK4—adipose tissue—type 2 diabetes mellitus	0.000257	0.00208	CbGeAlD
Bosutinib—EPHA4—adipose tissue—type 2 diabetes mellitus	0.000254	0.00206	CbGeAlD
Bosutinib—STK4—liver—type 2 diabetes mellitus	0.000254	0.00206	CbGeAlD
Bosutinib—RPS6KB1—cortex of kidney—type 2 diabetes mellitus	0.000254	0.00205	CbGeAlD
Bosutinib—SRC—retina—type 2 diabetes mellitus	0.000253	0.00205	CbGeAlD
Bosutinib—EPHB4—cardiovascular system—type 2 diabetes mellitus	0.000252	0.00204	CbGeAlD
Bosutinib—ERBB3—adipose tissue—type 2 diabetes mellitus	0.000251	0.00204	CbGeAlD
Bosutinib—AXL—cortex of kidney—type 2 diabetes mellitus	0.000251	0.00203	CbGeAlD
Bosutinib—MAP2K2—adipose tissue—type 2 diabetes mellitus	0.000251	0.00203	CbGeAlD
Bosutinib—ULK3—adipose tissue—type 2 diabetes mellitus	0.000251	0.00203	CbGeAlD
Bosutinib—CAMK1D—liver—type 2 diabetes mellitus	0.000251	0.00203	CbGeAlD
Bosutinib—MAP3K2—adipose tissue—type 2 diabetes mellitus	0.000249	0.00202	CbGeAlD
Bosutinib—STK24—liver—type 2 diabetes mellitus	0.000248	0.00201	CbGeAlD
Bosutinib—YES1—nephron tubule—type 2 diabetes mellitus	0.000248	0.00201	CbGeAlD
Bosutinib—EPHA2—cardiovascular system—type 2 diabetes mellitus	0.000247	0.002	CbGeAlD
Bosutinib—MAP3K7—adipose tissue—type 2 diabetes mellitus	0.000247	0.002	CbGeAlD
Bosutinib—FYN—cardiovascular system—type 2 diabetes mellitus	0.000247	0.002	CbGeAlD
Bosutinib—SLK—pancreas—type 2 diabetes mellitus	0.000246	0.002	CbGeAlD
Bosutinib—EPHB4—kidney—type 2 diabetes mellitus	0.000246	0.002	CbGeAlD
Bosutinib—EPHB4—pancreas—type 2 diabetes mellitus	0.000245	0.00198	CbGeAlD
Bosutinib—TAOK3—nephron tubule—type 2 diabetes mellitus	0.000245	0.00198	CbGeAlD
Bosutinib—TBK1—adipose tissue—type 2 diabetes mellitus	0.000244	0.00198	CbGeAlD
Bosutinib—PTK2—adipose tissue—type 2 diabetes mellitus	0.000244	0.00198	CbGeAlD
Bosutinib—SLK—cortex of kidney—type 2 diabetes mellitus	0.000242	0.00196	CbGeAlD
Bosutinib—FYN—kidney—type 2 diabetes mellitus	0.000241	0.00195	CbGeAlD
Bosutinib—MAP3K3—cardiovascular system—type 2 diabetes mellitus	0.000241	0.00195	CbGeAlD
Bosutinib—EPHA2—pancreas—type 2 diabetes mellitus	0.00024	0.00194	CbGeAlD
Bosutinib—FER—liver—type 2 diabetes mellitus	0.00024	0.00194	CbGeAlD
Bosutinib—EPHB4—cortex of kidney—type 2 diabetes mellitus	0.00024	0.00194	CbGeAlD
Bosutinib—IRAK1—adipose tissue—type 2 diabetes mellitus	0.000239	0.00194	CbGeAlD
Bosutinib—LYN—liver—type 2 diabetes mellitus	0.000239	0.00193	CbGeAlD
Bosutinib—PDGFRB—islet of Langerhans—type 2 diabetes mellitus	0.000236	0.00191	CbGeAlD
Bosutinib—FYN—cortex of kidney—type 2 diabetes mellitus	0.000235	0.0019	CbGeAlD
Bosutinib—RPS6KB1—adipose tissue—type 2 diabetes mellitus	0.000235	0.0019	CbGeAlD
Bosutinib—MAP4K5—pancreas—type 2 diabetes mellitus	0.000234	0.0019	CbGeAlD
Bosutinib—BTK—liver—type 2 diabetes mellitus	0.000234	0.00189	CbGeAlD
Bosutinib—LCK—adipose tissue—type 2 diabetes mellitus	0.000233	0.00189	CbGeAlD
Bosutinib—FGR—adipose tissue—type 2 diabetes mellitus	0.000233	0.00189	CbGeAlD
Bosutinib—AXL—adipose tissue—type 2 diabetes mellitus	0.000232	0.00188	CbGeAlD
Bosutinib—TNK2—liver—type 2 diabetes mellitus	0.00023	0.00187	CbGeAlD
Bosutinib—MAP4K5—cortex of kidney—type 2 diabetes mellitus	0.00023	0.00186	CbGeAlD
Bosutinib—MAP3K3—cortex of kidney—type 2 diabetes mellitus	0.00023	0.00186	CbGeAlD
Bosutinib—MAP4K2—liver—type 2 diabetes mellitus	0.000227	0.00184	CbGeAlD
Bosutinib—Vandetanib—CYP3A4—type 2 diabetes mellitus	0.000225	0.0613	CrCbGaD
Bosutinib—STK3—liver—type 2 diabetes mellitus	0.000224	0.00182	CbGeAlD
Bosutinib—SLK—adipose tissue—type 2 diabetes mellitus	0.000224	0.00181	CbGeAlD
Bosutinib—EPHB4—adipose tissue—type 2 diabetes mellitus	0.000222	0.0018	CbGeAlD
Bosutinib—ROCK1—liver—type 2 diabetes mellitus	0.000221	0.00179	CbGeAlD
Bosutinib—STK10—cardiovascular system—type 2 diabetes mellitus	0.00022	0.00179	CbGeAlD
Bosutinib—TAOK3—cardiovascular system—type 2 diabetes mellitus	0.00022	0.00178	CbGeAlD
Bosutinib—EPHA2—adipose tissue—type 2 diabetes mellitus	0.000218	0.00176	CbGeAlD
Bosutinib—YES1—kidney—type 2 diabetes mellitus	0.000218	0.00176	CbGeAlD
Bosutinib—FYN—adipose tissue—type 2 diabetes mellitus	0.000217	0.00176	CbGeAlD
Bosutinib—YES1—pancreas—type 2 diabetes mellitus	0.000216	0.00175	CbGeAlD
Bosutinib—STK10—kidney—type 2 diabetes mellitus	0.000216	0.00175	CbGeAlD
Bosutinib—BMPR2—liver—type 2 diabetes mellitus	0.000215	0.00174	CbGeAlD
Bosutinib—TAOK3—kidney—type 2 diabetes mellitus	0.000215	0.00174	CbGeAlD
Bosutinib—SRC—cardiovascular system—type 2 diabetes mellitus	0.000214	0.00173	CbGeAlD
Bosutinib—Gefitinib—CYP3A4—type 2 diabetes mellitus	0.000214	0.0583	CrCbGaD
Bosutinib—TAOK3—pancreas—type 2 diabetes mellitus	0.000213	0.00173	CbGeAlD
Bosutinib—STK36—liver—type 2 diabetes mellitus	0.000213	0.00173	CbGeAlD
Bosutinib—MAP4K5—adipose tissue—type 2 diabetes mellitus	0.000212	0.00172	CbGeAlD
Bosutinib—MAP3K3—adipose tissue—type 2 diabetes mellitus	0.000212	0.00172	CbGeAlD
Bosutinib—YES1—cortex of kidney—type 2 diabetes mellitus	0.000212	0.00172	CbGeAlD
Bosutinib—MERTK—liver—type 2 diabetes mellitus	0.000211	0.00171	CbGeAlD
Bosutinib—ABL1—islet of Langerhans—type 2 diabetes mellitus	0.00021	0.0017	CbGeAlD
Bosutinib—SRC—kidney—type 2 diabetes mellitus	0.000209	0.0017	CbGeAlD
Bosutinib—TAOK3—cortex of kidney—type 2 diabetes mellitus	0.000209	0.0017	CbGeAlD
Bosutinib—SRC—pancreas—type 2 diabetes mellitus	0.000208	0.00169	CbGeAlD
Bosutinib—MAP4K4—liver—type 2 diabetes mellitus	0.000207	0.00168	CbGeAlD
Bosutinib—NUAK2—liver—type 2 diabetes mellitus	0.000205	0.00166	CbGeAlD
Bosutinib—BCR—liver—type 2 diabetes mellitus	0.000205	0.00166	CbGeAlD
Bosutinib—MAP3K12—liver—type 2 diabetes mellitus	0.000204	0.00165	CbGeAlD
Bosutinib—MAP2K1—liver—type 2 diabetes mellitus	0.0002	0.00162	CbGeAlD
Bosutinib—STK35—liver—type 2 diabetes mellitus	0.0002	0.00162	CbGeAlD
Bosutinib—CSK—liver—type 2 diabetes mellitus	0.000198	0.00161	CbGeAlD
Bosutinib—CSNK1A1—liver—type 2 diabetes mellitus	0.000197	0.0016	CbGeAlD
Bosutinib—MAP2K5—cardiovascular system—type 2 diabetes mellitus	0.000197	0.0016	CbGeAlD
Bosutinib—YES1—adipose tissue—type 2 diabetes mellitus	0.000196	0.00159	CbGeAlD
Bosutinib—Vandetanib—ALB—type 2 diabetes mellitus	0.000196	0.0535	CrCbGaD
Bosutinib—HCK—liver—type 2 diabetes mellitus	0.000196	0.00159	CbGeAlD
Bosutinib—CLK1—liver—type 2 diabetes mellitus	0.000196	0.00159	CbGeAlD
Bosutinib—ABL2—liver—type 2 diabetes mellitus	0.000195	0.00158	CbGeAlD
Bosutinib—STK10—adipose tissue—type 2 diabetes mellitus	0.000194	0.00158	CbGeAlD
Bosutinib—TAOK3—adipose tissue—type 2 diabetes mellitus	0.000194	0.00157	CbGeAlD
Bosutinib—CAMK2G—liver—type 2 diabetes mellitus	0.000192	0.00156	CbGeAlD
Bosutinib—BMP2K—liver—type 2 diabetes mellitus	0.000192	0.00156	CbGeAlD
Bosutinib—CSF1R—cardiovascular system—type 2 diabetes mellitus	0.000192	0.00156	CbGeAlD
Bosutinib—LRRK2—liver—type 2 diabetes mellitus	0.000191	0.00154	CbGeAlD
Bosutinib—EGFR—liver—type 2 diabetes mellitus	0.00019	0.00154	CbGeAlD
Bosutinib—SRC—adipose tissue—type 2 diabetes mellitus	0.000189	0.00153	CbGeAlD
Bosutinib—MAP2K5—cortex of kidney—type 2 diabetes mellitus	0.000188	0.00152	CbGeAlD
Bosutinib—Gefitinib—ALB—type 2 diabetes mellitus	0.000186	0.0508	CrCbGaD
Bosutinib—PTK2B—liver—type 2 diabetes mellitus	0.000186	0.00151	CbGeAlD
Bosutinib—CSNK1E—liver—type 2 diabetes mellitus	0.000183	0.00148	CbGeAlD
Bosutinib—SIK1—liver—type 2 diabetes mellitus	0.00018	0.00146	CbGeAlD
Bosutinib—IRAK4—liver—type 2 diabetes mellitus	0.00018	0.00146	CbGeAlD
Bosutinib—ABL1—retina—type 2 diabetes mellitus	0.00018	0.00146	CbGeAlD
Bosutinib—ERBB3—liver—type 2 diabetes mellitus	0.000176	0.00143	CbGeAlD
Bosutinib—ULK3—liver—type 2 diabetes mellitus	0.000176	0.00143	CbGeAlD
Bosutinib—MAP2K2—liver—type 2 diabetes mellitus	0.000176	0.00143	CbGeAlD
Bosutinib—MAP3K2—liver—type 2 diabetes mellitus	0.000175	0.00142	CbGeAlD
Bosutinib—MAP2K5—adipose tissue—type 2 diabetes mellitus	0.000174	0.00141	CbGeAlD
Bosutinib—MAP3K7—liver—type 2 diabetes mellitus	0.000173	0.0014	CbGeAlD
Bosutinib—PTK2—liver—type 2 diabetes mellitus	0.000171	0.00139	CbGeAlD
Bosutinib—TBK1—liver—type 2 diabetes mellitus	0.000171	0.00139	CbGeAlD
Bosutinib—PDGFRB—cardiovascular system—type 2 diabetes mellitus	0.00017	0.00138	CbGeAlD
Bosutinib—CSF1R—adipose tissue—type 2 diabetes mellitus	0.000169	0.00137	CbGeAlD
Bosutinib—ABL1—nephron tubule—type 2 diabetes mellitus	0.000169	0.00137	CbGeAlD
Bosutinib—IRAK1—liver—type 2 diabetes mellitus	0.000168	0.00136	CbGeAlD
Bosutinib—PDGFRB—kidney—type 2 diabetes mellitus	0.000167	0.00135	CbGeAlD
Bosutinib—PDGFRB—pancreas—type 2 diabetes mellitus	0.000166	0.00134	CbGeAlD
Bosutinib—RPS6KB1—liver—type 2 diabetes mellitus	0.000165	0.00133	CbGeAlD
Bosutinib—FGR—liver—type 2 diabetes mellitus	0.000164	0.00133	CbGeAlD
Bosutinib—LCK—liver—type 2 diabetes mellitus	0.000164	0.00133	CbGeAlD
Bosutinib—AXL—liver—type 2 diabetes mellitus	0.000163	0.00132	CbGeAlD
Bosutinib—PDGFRB—cortex of kidney—type 2 diabetes mellitus	0.000162	0.00132	CbGeAlD
Bosutinib—SLK—liver—type 2 diabetes mellitus	0.000157	0.00127	CbGeAlD
Bosutinib—EPHB4—liver—type 2 diabetes mellitus	0.000156	0.00126	CbGeAlD
Bosutinib—EPHA2—liver—type 2 diabetes mellitus	0.000153	0.00124	CbGeAlD
Bosutinib—FYN—liver—type 2 diabetes mellitus	0.000152	0.00124	CbGeAlD
Bosutinib—ABL1—cardiovascular system—type 2 diabetes mellitus	0.000152	0.00123	CbGeAlD
Bosutinib—PDGFRB—adipose tissue—type 2 diabetes mellitus	0.00015	0.00122	CbGeAlD
Bosutinib—MAP4K5—liver—type 2 diabetes mellitus	0.000149	0.00121	CbGeAlD
Bosutinib—MAP3K3—liver—type 2 diabetes mellitus	0.000149	0.00121	CbGeAlD
Bosutinib—ABL1—kidney—type 2 diabetes mellitus	0.000149	0.0012	CbGeAlD
Bosutinib—ABL1—pancreas—type 2 diabetes mellitus	0.000148	0.0012	CbGeAlD
Bosutinib—ABL1—cortex of kidney—type 2 diabetes mellitus	0.000145	0.00117	CbGeAlD
Bosutinib—YES1—liver—type 2 diabetes mellitus	0.000138	0.00111	CbGeAlD
Bosutinib—Discomfort—Orlistat—type 2 diabetes mellitus	0.000138	0.000757	CcSEcCtD
Bosutinib—Agranulocytosis—Ramipril—type 2 diabetes mellitus	0.000137	0.000754	CcSEcCtD
Bosutinib—STK10—liver—type 2 diabetes mellitus	0.000136	0.0011	CbGeAlD
Bosutinib—Malaise—Metformin—type 2 diabetes mellitus	0.000136	0.000748	CcSEcCtD
Bosutinib—TAOK3—liver—type 2 diabetes mellitus	0.000136	0.0011	CbGeAlD
Bosutinib—Diarrhoea—Glimepiride—type 2 diabetes mellitus	0.000136	0.000747	CcSEcCtD
Bosutinib—Diarrhoea—Sitagliptin—type 2 diabetes mellitus	0.000135	0.000745	CcSEcCtD
Bosutinib—Vomiting—Glipizide—type 2 diabetes mellitus	0.000135	0.000744	CcSEcCtD
Bosutinib—Oedema—Valsartan—type 2 diabetes mellitus	0.000135	0.000743	CcSEcCtD
Bosutinib—Anaphylactic shock—Valsartan—type 2 diabetes mellitus	0.000135	0.000743	CcSEcCtD
Bosutinib—Feeling abnormal—Glyburide—type 2 diabetes mellitus	0.000135	0.000742	CcSEcCtD
Bosutinib—Dizziness—Pioglitazone—type 2 diabetes mellitus	0.000135	0.000741	CcSEcCtD
Bosutinib—Infection—Valsartan—type 2 diabetes mellitus	0.000134	0.000738	CcSEcCtD
Bosutinib—Rash—Glipizide—type 2 diabetes mellitus	0.000134	0.000738	CcSEcCtD
Bosutinib—Dermatitis—Glipizide—type 2 diabetes mellitus	0.000134	0.000737	CcSEcCtD
Bosutinib—ABL1—adipose tissue—type 2 diabetes mellitus	0.000134	0.00109	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Gliclazide—type 2 diabetes mellitus	0.000134	0.000737	CcSEcCtD
Bosutinib—Gastrointestinal pain—Glyburide—type 2 diabetes mellitus	0.000134	0.000736	CcSEcCtD
Bosutinib—Anaphylactic shock—Orlistat—type 2 diabetes mellitus	0.000133	0.000734	CcSEcCtD
Bosutinib—Oedema—Orlistat—type 2 diabetes mellitus	0.000133	0.000734	CcSEcCtD
Bosutinib—Headache—Glipizide—type 2 diabetes mellitus	0.000133	0.000733	CcSEcCtD
Bosutinib—Infection—Orlistat—type 2 diabetes mellitus	0.000133	0.000729	CcSEcCtD
Bosutinib—Nervous system disorder—Valsartan—type 2 diabetes mellitus	0.000132	0.000729	CcSEcCtD
Bosutinib—SRC—liver—type 2 diabetes mellitus	0.000132	0.00107	CbGeAlD
Bosutinib—Thrombocytopenia—Valsartan—type 2 diabetes mellitus	0.000132	0.000727	CcSEcCtD
Bosutinib—Ill-defined disorder—Irbesartan—type 2 diabetes mellitus	0.000132	0.000726	CcSEcCtD
Bosutinib—Hepatitis—Ramipril—type 2 diabetes mellitus	0.000132	0.000725	CcSEcCtD
Bosutinib—Anaemia—Irbesartan—type 2 diabetes mellitus	0.000131	0.000723	CcSEcCtD
Bosutinib—Dizziness—Glimepiride—type 2 diabetes mellitus	0.000131	0.000722	CcSEcCtD
Bosutinib—Skin disorder—Valsartan—type 2 diabetes mellitus	0.000131	0.000722	CcSEcCtD
Bosutinib—Dysgeusia—Losartan—type 2 diabetes mellitus	0.000131	0.000721	CcSEcCtD
Bosutinib—Dyspnoea—Gliclazide—type 2 diabetes mellitus	0.000131	0.000721	CcSEcCtD
Bosutinib—Nervous system disorder—Orlistat—type 2 diabetes mellitus	0.000131	0.00072	CcSEcCtD
Bosutinib—Dizziness—Sitagliptin—type 2 diabetes mellitus	0.000131	0.00072	CcSEcCtD
Bosutinib—Urticaria—Glyburide—type 2 diabetes mellitus	0.00013	0.000715	CcSEcCtD
Bosutinib—Oedema peripheral—Ramipril—type 2 diabetes mellitus	0.00013	0.000714	CcSEcCtD
Bosutinib—Skin disorder—Orlistat—type 2 diabetes mellitus	0.00013	0.000713	CcSEcCtD
Bosutinib—Connective tissue disorder—Ramipril—type 2 diabetes mellitus	0.00013	0.000713	CcSEcCtD
Bosutinib—Back pain—Losartan—type 2 diabetes mellitus	0.000129	0.000712	CcSEcCtD
Bosutinib—Abdominal pain—Glyburide—type 2 diabetes mellitus	0.000129	0.000712	CcSEcCtD
Bosutinib—Asthenia—Bromocriptine—type 2 diabetes mellitus	0.000128	0.000707	CcSEcCtD
Bosutinib—Myalgia—Metformin—type 2 diabetes mellitus	0.000128	0.000706	CcSEcCtD
Bosutinib—Chest pain—Metformin—type 2 diabetes mellitus	0.000128	0.000706	CcSEcCtD
Bosutinib—Malaise—Irbesartan—type 2 diabetes mellitus	0.000128	0.000705	CcSEcCtD
Bosutinib—Headache—Pioglitazone—type 2 diabetes mellitus	0.000128	0.000702	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Metformin—type 2 diabetes mellitus	0.000127	0.000701	CcSEcCtD
Bosutinib—Leukopenia—Irbesartan—type 2 diabetes mellitus	0.000127	0.0007	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Gliclazide—type 2 diabetes mellitus	0.000127	0.000698	CcSEcCtD
Bosutinib—Discomfort—Metformin—type 2 diabetes mellitus	0.000127	0.000697	CcSEcCtD
Bosutinib—Fatigue—Gliclazide—type 2 diabetes mellitus	0.000127	0.000697	CcSEcCtD
Bosutinib—Nausea—Glipizide—type 2 diabetes mellitus	0.000126	0.000695	CcSEcCtD
Bosutinib—Vomiting—Glimepiride—type 2 diabetes mellitus	0.000126	0.000694	CcSEcCtD
Bosutinib—Vomiting—Sitagliptin—type 2 diabetes mellitus	0.000126	0.000692	CcSEcCtD
Bosutinib—Pain—Gliclazide—type 2 diabetes mellitus	0.000126	0.000691	CcSEcCtD
Bosutinib—Rash—Glimepiride—type 2 diabetes mellitus	0.000125	0.000688	CcSEcCtD
Bosutinib—Dermatitis—Glimepiride—type 2 diabetes mellitus	0.000125	0.000688	CcSEcCtD
Bosutinib—Rash—Sitagliptin—type 2 diabetes mellitus	0.000125	0.000686	CcSEcCtD
Bosutinib—Dermatitis—Sitagliptin—type 2 diabetes mellitus	0.000125	0.000686	CcSEcCtD
Bosutinib—Erythema multiforme—Ramipril—type 2 diabetes mellitus	0.000125	0.000686	CcSEcCtD
Bosutinib—Headache—Glimepiride—type 2 diabetes mellitus	0.000124	0.000684	CcSEcCtD
Bosutinib—Ill-defined disorder—Losartan—type 2 diabetes mellitus	0.000124	0.000683	CcSEcCtD
Bosutinib—Cough—Irbesartan—type 2 diabetes mellitus	0.000124	0.000683	CcSEcCtD
Bosutinib—Headache—Sitagliptin—type 2 diabetes mellitus	0.000124	0.000682	CcSEcCtD
Bosutinib—Anaemia—Losartan—type 2 diabetes mellitus	0.000124	0.00068	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Valsartan—type 2 diabetes mellitus	0.000123	0.000677	CcSEcCtD
Bosutinib—Oedema—Metformin—type 2 diabetes mellitus	0.000123	0.000677	CcSEcCtD
Bosutinib—Tinnitus—Ramipril—type 2 diabetes mellitus	0.000123	0.000676	CcSEcCtD
Bosutinib—Diarrhoea—Bromocriptine—type 2 diabetes mellitus	0.000122	0.000674	CcSEcCtD
Bosutinib—Infection—Metformin—type 2 diabetes mellitus	0.000122	0.000672	CcSEcCtD
Bosutinib—MAP2K5—liver—type 2 diabetes mellitus	0.000122	0.000987	CbGeAlD
Bosutinib—Musculoskeletal discomfort—Orlistat—type 2 diabetes mellitus	0.000122	0.000669	CcSEcCtD
Bosutinib—Feeling abnormal—Gliclazide—type 2 diabetes mellitus	0.000121	0.000666	CcSEcCtD
Bosutinib—Chest pain—Irbesartan—type 2 diabetes mellitus	0.000121	0.000666	CcSEcCtD
Bosutinib—Myalgia—Irbesartan—type 2 diabetes mellitus	0.000121	0.000666	CcSEcCtD
Bosutinib—Arthralgia—Irbesartan—type 2 diabetes mellitus	0.000121	0.000666	CcSEcCtD
Bosutinib—Malaise—Losartan—type 2 diabetes mellitus	0.000121	0.000664	CcSEcCtD
Bosutinib—Nervous system disorder—Metformin—type 2 diabetes mellitus	0.000121	0.000663	CcSEcCtD
Bosutinib—Thrombocytopenia—Metformin—type 2 diabetes mellitus	0.00012	0.000662	CcSEcCtD
Bosutinib—Dyspnoea—Valsartan—type 2 diabetes mellitus	0.00012	0.000662	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Irbesartan—type 2 diabetes mellitus	0.00012	0.000661	CcSEcCtD
Bosutinib—Gastrointestinal pain—Gliclazide—type 2 diabetes mellitus	0.00012	0.000661	CcSEcCtD
Bosutinib—Leukopenia—Losartan—type 2 diabetes mellitus	0.00012	0.000659	CcSEcCtD
Bosutinib—Discomfort—Irbesartan—type 2 diabetes mellitus	0.00012	0.000658	CcSEcCtD
Bosutinib—Skin disorder—Metformin—type 2 diabetes mellitus	0.000119	0.000657	CcSEcCtD
Bosutinib—Immune system disorder—Ramipril—type 2 diabetes mellitus	0.000119	0.000655	CcSEcCtD
Bosutinib—CSF1R—liver—type 2 diabetes mellitus	0.000119	0.000963	CbGeAlD
Bosutinib—Mediastinal disorder—Ramipril—type 2 diabetes mellitus	0.000119	0.000654	CcSEcCtD
Bosutinib—Dizziness—Bromocriptine—type 2 diabetes mellitus	0.000118	0.000651	CcSEcCtD
Bosutinib—Nausea—Glimepiride—type 2 diabetes mellitus	0.000118	0.000649	CcSEcCtD
Bosutinib—Nausea—Sitagliptin—type 2 diabetes mellitus	0.000117	0.000647	CcSEcCtD
Bosutinib—Asthenia—Glyburide—type 2 diabetes mellitus	0.000117	0.000646	CcSEcCtD
Bosutinib—Decreased appetite—Valsartan—type 2 diabetes mellitus	0.000117	0.000646	CcSEcCtD
Bosutinib—Cough—Losartan—type 2 diabetes mellitus	0.000117	0.000642	CcSEcCtD
Bosutinib—Urticaria—Gliclazide—type 2 diabetes mellitus	0.000117	0.000642	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Valsartan—type 2 diabetes mellitus	0.000117	0.000641	CcSEcCtD
Bosutinib—Fatigue—Valsartan—type 2 diabetes mellitus	0.000116	0.00064	CcSEcCtD
Bosutinib—Body temperature increased—Gliclazide—type 2 diabetes mellitus	0.000116	0.000639	CcSEcCtD
Bosutinib—Abdominal pain—Gliclazide—type 2 diabetes mellitus	0.000116	0.000639	CcSEcCtD
Bosutinib—Oedema—Irbesartan—type 2 diabetes mellitus	0.000116	0.000638	CcSEcCtD
Bosutinib—Anaphylactic shock—Irbesartan—type 2 diabetes mellitus	0.000116	0.000638	CcSEcCtD
Bosutinib—Decreased appetite—Orlistat—type 2 diabetes mellitus	0.000116	0.000638	CcSEcCtD
Bosutinib—Pruritus—Glyburide—type 2 diabetes mellitus	0.000116	0.000637	CcSEcCtD
Bosutinib—Infection—Irbesartan—type 2 diabetes mellitus	0.000115	0.000634	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Orlistat—type 2 diabetes mellitus	0.000115	0.000634	CcSEcCtD
Bosutinib—Fatigue—Orlistat—type 2 diabetes mellitus	0.000115	0.000633	CcSEcCtD
Bosutinib—Malnutrition—Ramipril—type 2 diabetes mellitus	0.000115	0.000631	CcSEcCtD
Bosutinib—Pain—Orlistat—type 2 diabetes mellitus	0.000114	0.000628	CcSEcCtD
Bosutinib—Arthralgia—Losartan—type 2 diabetes mellitus	0.000114	0.000627	CcSEcCtD
Bosutinib—Chest pain—Losartan—type 2 diabetes mellitus	0.000114	0.000627	CcSEcCtD
Bosutinib—Myalgia—Losartan—type 2 diabetes mellitus	0.000114	0.000627	CcSEcCtD
Bosutinib—Vomiting—Bromocriptine—type 2 diabetes mellitus	0.000114	0.000626	CcSEcCtD
Bosutinib—Nervous system disorder—Irbesartan—type 2 diabetes mellitus	0.000114	0.000626	CcSEcCtD
Bosutinib—Thrombocytopenia—Irbesartan—type 2 diabetes mellitus	0.000114	0.000625	CcSEcCtD
Bosutinib—Rash—Bromocriptine—type 2 diabetes mellitus	0.000113	0.000621	CcSEcCtD
Bosutinib—Dermatitis—Bromocriptine—type 2 diabetes mellitus	0.000113	0.000621	CcSEcCtD
Bosutinib—Skin disorder—Irbesartan—type 2 diabetes mellitus	0.000113	0.00062	CcSEcCtD
Bosutinib—Discomfort—Losartan—type 2 diabetes mellitus	0.000113	0.000619	CcSEcCtD
Bosutinib—Dysgeusia—Ramipril—type 2 diabetes mellitus	0.000112	0.000618	CcSEcCtD
Bosutinib—Headache—Bromocriptine—type 2 diabetes mellitus	0.000112	0.000617	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Metformin—type 2 diabetes mellitus	0.000112	0.000616	CcSEcCtD
Bosutinib—Diarrhoea—Glyburide—type 2 diabetes mellitus	0.000112	0.000616	CcSEcCtD
Bosutinib—Gastrointestinal pain—Valsartan—type 2 diabetes mellitus	0.00011	0.000607	CcSEcCtD
Bosutinib—Feeling abnormal—Orlistat—type 2 diabetes mellitus	0.00011	0.000605	CcSEcCtD
Bosutinib—Dyspnoea—Metformin—type 2 diabetes mellitus	0.00011	0.000603	CcSEcCtD
Bosutinib—Anaphylactic shock—Losartan—type 2 diabetes mellitus	0.000109	0.000601	CcSEcCtD
Bosutinib—Oedema—Losartan—type 2 diabetes mellitus	0.000109	0.000601	CcSEcCtD
Bosutinib—Gastrointestinal pain—Orlistat—type 2 diabetes mellitus	0.000109	0.0006	CcSEcCtD
Bosutinib—Infection—Losartan—type 2 diabetes mellitus	0.000108	0.000597	CcSEcCtD
Bosutinib—Urticaria—Valsartan—type 2 diabetes mellitus	0.000107	0.00059	CcSEcCtD
Bosutinib—Nervous system disorder—Losartan—type 2 diabetes mellitus	0.000107	0.000589	CcSEcCtD
Bosutinib—Thrombocytopenia—Losartan—type 2 diabetes mellitus	0.000107	0.000588	CcSEcCtD
Bosutinib—Decreased appetite—Metformin—type 2 diabetes mellitus	0.000107	0.000588	CcSEcCtD
Bosutinib—Abdominal pain—Valsartan—type 2 diabetes mellitus	0.000107	0.000587	CcSEcCtD
Bosutinib—Ill-defined disorder—Ramipril—type 2 diabetes mellitus	0.000106	0.000586	CcSEcCtD
Bosutinib—Nausea—Bromocriptine—type 2 diabetes mellitus	0.000106	0.000585	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Metformin—type 2 diabetes mellitus	0.000106	0.000584	CcSEcCtD
Bosutinib—Fatigue—Metformin—type 2 diabetes mellitus	0.000106	0.000583	CcSEcCtD
Bosutinib—Urticaria—Orlistat—type 2 diabetes mellitus	0.000106	0.000583	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Irbesartan—type 2 diabetes mellitus	0.000106	0.000582	CcSEcCtD
Bosutinib—Abdominal pain—Orlistat—type 2 diabetes mellitus	0.000105	0.00058	CcSEcCtD
Bosutinib—Body temperature increased—Orlistat—type 2 diabetes mellitus	0.000105	0.00058	CcSEcCtD
Bosutinib—Asthenia—Gliclazide—type 2 diabetes mellitus	0.000105	0.00058	CcSEcCtD
Bosutinib—PDGFRB—liver—type 2 diabetes mellitus	0.000105	0.000854	CbGeAlD
Bosutinib—Vomiting—Glyburide—type 2 diabetes mellitus	0.000104	0.000573	CcSEcCtD
Bosutinib—Pruritus—Gliclazide—type 2 diabetes mellitus	0.000104	0.000572	CcSEcCtD
Bosutinib—Malaise—Ramipril—type 2 diabetes mellitus	0.000103	0.000569	CcSEcCtD
Bosutinib—Dyspnoea—Irbesartan—type 2 diabetes mellitus	0.000103	0.000569	CcSEcCtD
Bosutinib—Rash—Glyburide—type 2 diabetes mellitus	0.000103	0.000568	CcSEcCtD
Bosutinib—Dermatitis—Glyburide—type 2 diabetes mellitus	0.000103	0.000567	CcSEcCtD
Bosutinib—Leukopenia—Ramipril—type 2 diabetes mellitus	0.000103	0.000565	CcSEcCtD
Bosutinib—Headache—Glyburide—type 2 diabetes mellitus	0.000103	0.000564	CcSEcCtD
Bosutinib—Feeling abnormal—Metformin—type 2 diabetes mellitus	0.000101	0.000557	CcSEcCtD
Bosutinib—Decreased appetite—Irbesartan—type 2 diabetes mellitus	0.000101	0.000555	CcSEcCtD
Bosutinib—Diarrhoea—Gliclazide—type 2 diabetes mellitus	0.000101	0.000553	CcSEcCtD
Bosutinib—Gastrointestinal pain—Metformin—type 2 diabetes mellitus	0.000101	0.000553	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Irbesartan—type 2 diabetes mellitus	0.0001	0.000551	CcSEcCtD
Bosutinib—Cough—Ramipril—type 2 diabetes mellitus	0.0001	0.000551	CcSEcCtD
Bosutinib—Fatigue—Irbesartan—type 2 diabetes mellitus	0.0001	0.00055	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Losartan—type 2 diabetes mellitus	9.95e-05	0.000547	CcSEcCtD
Bosutinib—Pain—Irbesartan—type 2 diabetes mellitus	9.92e-05	0.000546	CcSEcCtD
Bosutinib—Urticaria—Metformin—type 2 diabetes mellitus	9.77e-05	0.000537	CcSEcCtD
Bosutinib—Chest pain—Ramipril—type 2 diabetes mellitus	9.77e-05	0.000537	CcSEcCtD
Bosutinib—Arthralgia—Ramipril—type 2 diabetes mellitus	9.77e-05	0.000537	CcSEcCtD
Bosutinib—Myalgia—Ramipril—type 2 diabetes mellitus	9.77e-05	0.000537	CcSEcCtD
Bosutinib—Dyspnoea—Losartan—type 2 diabetes mellitus	9.74e-05	0.000536	CcSEcCtD
Bosutinib—Nausea—Glyburide—type 2 diabetes mellitus	9.72e-05	0.000535	CcSEcCtD
Bosutinib—Abdominal pain—Metformin—type 2 diabetes mellitus	9.72e-05	0.000535	CcSEcCtD
Bosutinib—Dizziness—Gliclazide—type 2 diabetes mellitus	9.72e-05	0.000535	CcSEcCtD
Bosutinib—Unspecified disorder of skin and subcutaneous tissue—Ramipril—type 2 diabetes mellitus	9.7e-05	0.000534	CcSEcCtD
Bosutinib—Asthenia—Valsartan—type 2 diabetes mellitus	9.69e-05	0.000533	CcSEcCtD
Bosutinib—Discomfort—Ramipril—type 2 diabetes mellitus	9.65e-05	0.000531	CcSEcCtD
Bosutinib—Asthenia—Orlistat—type 2 diabetes mellitus	9.57e-05	0.000527	CcSEcCtD
Bosutinib—Feeling abnormal—Irbesartan—type 2 diabetes mellitus	9.56e-05	0.000526	CcSEcCtD
Bosutinib—Pruritus—Valsartan—type 2 diabetes mellitus	9.55e-05	0.000526	CcSEcCtD
Bosutinib—Decreased appetite—Losartan—type 2 diabetes mellitus	9.49e-05	0.000522	CcSEcCtD
Bosutinib—Gastrointestinal pain—Irbesartan—type 2 diabetes mellitus	9.49e-05	0.000522	CcSEcCtD
Bosutinib—Pruritus—Orlistat—type 2 diabetes mellitus	9.44e-05	0.000519	CcSEcCtD
Bosutinib—Fatigue—Losartan—type 2 diabetes mellitus	9.41e-05	0.000518	CcSEcCtD
Bosutinib—ABL1—liver—type 2 diabetes mellitus	9.39e-05	0.000761	CbGeAlD
Bosutinib—Oedema—Ramipril—type 2 diabetes mellitus	9.36e-05	0.000515	CcSEcCtD
Bosutinib—Anaphylactic shock—Ramipril—type 2 diabetes mellitus	9.36e-05	0.000515	CcSEcCtD
Bosutinib—Vomiting—Gliclazide—type 2 diabetes mellitus	9.34e-05	0.000514	CcSEcCtD
Bosutinib—Pain—Losartan—type 2 diabetes mellitus	9.34e-05	0.000514	CcSEcCtD
Bosutinib—Rash—Gliclazide—type 2 diabetes mellitus	9.27e-05	0.00051	CcSEcCtD
Bosutinib—Dermatitis—Gliclazide—type 2 diabetes mellitus	9.26e-05	0.000509	CcSEcCtD
Bosutinib—Diarrhoea—Valsartan—type 2 diabetes mellitus	9.24e-05	0.000508	CcSEcCtD
Bosutinib—Urticaria—Irbesartan—type 2 diabetes mellitus	9.22e-05	0.000507	CcSEcCtD
Bosutinib—Headache—Gliclazide—type 2 diabetes mellitus	9.21e-05	0.000507	CcSEcCtD
Bosutinib—Nervous system disorder—Ramipril—type 2 diabetes mellitus	9.18e-05	0.000505	CcSEcCtD
Bosutinib—Abdominal pain—Irbesartan—type 2 diabetes mellitus	9.17e-05	0.000505	CcSEcCtD
Bosutinib—Body temperature increased—Irbesartan—type 2 diabetes mellitus	9.17e-05	0.000505	CcSEcCtD
Bosutinib—Thrombocytopenia—Ramipril—type 2 diabetes mellitus	9.17e-05	0.000504	CcSEcCtD
Bosutinib—Diarrhoea—Orlistat—type 2 diabetes mellitus	9.13e-05	0.000502	CcSEcCtD
Bosutinib—Skin disorder—Ramipril—type 2 diabetes mellitus	9.09e-05	0.0005	CcSEcCtD
Bosutinib—Feeling abnormal—Losartan—type 2 diabetes mellitus	9e-05	0.000495	CcSEcCtD
Bosutinib—Gastrointestinal pain—Losartan—type 2 diabetes mellitus	8.93e-05	0.000491	CcSEcCtD
Bosutinib—Dizziness—Valsartan—type 2 diabetes mellitus	8.93e-05	0.000491	CcSEcCtD
Bosutinib—Dizziness—Orlistat—type 2 diabetes mellitus	8.82e-05	0.000485	CcSEcCtD
Bosutinib—Asthenia—Metformin—type 2 diabetes mellitus	8.82e-05	0.000485	CcSEcCtD
Bosutinib—Nausea—Gliclazide—type 2 diabetes mellitus	8.73e-05	0.00048	CcSEcCtD
Bosutinib—Pruritus—Metformin—type 2 diabetes mellitus	8.7e-05	0.000479	CcSEcCtD
Bosutinib—Urticaria—Losartan—type 2 diabetes mellitus	8.67e-05	0.000477	CcSEcCtD
Bosutinib—Abdominal pain—Losartan—type 2 diabetes mellitus	8.63e-05	0.000475	CcSEcCtD
Bosutinib—Body temperature increased—Losartan—type 2 diabetes mellitus	8.63e-05	0.000475	CcSEcCtD
Bosutinib—Vomiting—Valsartan—type 2 diabetes mellitus	8.58e-05	0.000472	CcSEcCtD
Bosutinib—Musculoskeletal discomfort—Ramipril—type 2 diabetes mellitus	8.53e-05	0.000469	CcSEcCtD
Bosutinib—Rash—Valsartan—type 2 diabetes mellitus	8.51e-05	0.000468	CcSEcCtD
Bosutinib—Dermatitis—Valsartan—type 2 diabetes mellitus	8.5e-05	0.000468	CcSEcCtD
Bosutinib—Vomiting—Orlistat—type 2 diabetes mellitus	8.48e-05	0.000467	CcSEcCtD
Bosutinib—Headache—Valsartan—type 2 diabetes mellitus	8.46e-05	0.000465	CcSEcCtD
Bosutinib—Diarrhoea—Metformin—type 2 diabetes mellitus	8.41e-05	0.000463	CcSEcCtD
Bosutinib—Rash—Orlistat—type 2 diabetes mellitus	8.41e-05	0.000463	CcSEcCtD
Bosutinib—Dermatitis—Orlistat—type 2 diabetes mellitus	8.4e-05	0.000462	CcSEcCtD
Bosutinib—Headache—Orlistat—type 2 diabetes mellitus	8.36e-05	0.00046	CcSEcCtD
Bosutinib—Dyspnoea—Ramipril—type 2 diabetes mellitus	8.35e-05	0.000459	CcSEcCtD
Bosutinib—Asthenia—Irbesartan—type 2 diabetes mellitus	8.32e-05	0.000458	CcSEcCtD
Bosutinib—Pruritus—Irbesartan—type 2 diabetes mellitus	8.21e-05	0.000452	CcSEcCtD
Bosutinib—Decreased appetite—Ramipril—type 2 diabetes mellitus	8.14e-05	0.000448	CcSEcCtD
Bosutinib—Dizziness—Metformin—type 2 diabetes mellitus	8.13e-05	0.000447	CcSEcCtD
Bosutinib—Gastrointestinal disorder—Ramipril—type 2 diabetes mellitus	8.08e-05	0.000445	CcSEcCtD
Bosutinib—Fatigue—Ramipril—type 2 diabetes mellitus	8.07e-05	0.000444	CcSEcCtD
Bosutinib—Nausea—Valsartan—type 2 diabetes mellitus	8.02e-05	0.000441	CcSEcCtD
Bosutinib—Diarrhoea—Irbesartan—type 2 diabetes mellitus	7.94e-05	0.000437	CcSEcCtD
Bosutinib—Nausea—Orlistat—type 2 diabetes mellitus	7.92e-05	0.000436	CcSEcCtD
Bosutinib—Asthenia—Losartan—type 2 diabetes mellitus	7.83e-05	0.000431	CcSEcCtD
Bosutinib—Vomiting—Metformin—type 2 diabetes mellitus	7.82e-05	0.00043	CcSEcCtD
Bosutinib—Rash—Metformin—type 2 diabetes mellitus	7.75e-05	0.000427	CcSEcCtD
Bosutinib—Dermatitis—Metformin—type 2 diabetes mellitus	7.75e-05	0.000426	CcSEcCtD
Bosutinib—Pruritus—Losartan—type 2 diabetes mellitus	7.73e-05	0.000425	CcSEcCtD
Bosutinib—Feeling abnormal—Ramipril—type 2 diabetes mellitus	7.72e-05	0.000425	CcSEcCtD
Bosutinib—Headache—Metformin—type 2 diabetes mellitus	7.7e-05	0.000424	CcSEcCtD
Bosutinib—Dizziness—Irbesartan—type 2 diabetes mellitus	7.67e-05	0.000422	CcSEcCtD
Bosutinib—Gastrointestinal pain—Ramipril—type 2 diabetes mellitus	7.66e-05	0.000421	CcSEcCtD
Bosutinib—Diarrhoea—Losartan—type 2 diabetes mellitus	7.47e-05	0.000411	CcSEcCtD
Bosutinib—Urticaria—Ramipril—type 2 diabetes mellitus	7.44e-05	0.000409	CcSEcCtD
Bosutinib—Abdominal pain—Ramipril—type 2 diabetes mellitus	7.4e-05	0.000407	CcSEcCtD
Bosutinib—Body temperature increased—Ramipril—type 2 diabetes mellitus	7.4e-05	0.000407	CcSEcCtD
Bosutinib—Vomiting—Irbesartan—type 2 diabetes mellitus	7.38e-05	0.000406	CcSEcCtD
Bosutinib—Rash—Irbesartan—type 2 diabetes mellitus	7.32e-05	0.000403	CcSEcCtD
Bosutinib—Dermatitis—Irbesartan—type 2 diabetes mellitus	7.31e-05	0.000402	CcSEcCtD
Bosutinib—Nausea—Metformin—type 2 diabetes mellitus	7.3e-05	0.000402	CcSEcCtD
Bosutinib—Headache—Irbesartan—type 2 diabetes mellitus	7.27e-05	0.0004	CcSEcCtD
Bosutinib—Dizziness—Losartan—type 2 diabetes mellitus	7.22e-05	0.000397	CcSEcCtD
Bosutinib—Vomiting—Losartan—type 2 diabetes mellitus	6.94e-05	0.000382	CcSEcCtD
Bosutinib—Nausea—Irbesartan—type 2 diabetes mellitus	6.89e-05	0.000379	CcSEcCtD
Bosutinib—Rash—Losartan—type 2 diabetes mellitus	6.88e-05	0.000379	CcSEcCtD
Bosutinib—Dermatitis—Losartan—type 2 diabetes mellitus	6.88e-05	0.000378	CcSEcCtD
Bosutinib—Headache—Losartan—type 2 diabetes mellitus	6.84e-05	0.000376	CcSEcCtD
Bosutinib—Asthenia—Ramipril—type 2 diabetes mellitus	6.72e-05	0.00037	CcSEcCtD
Bosutinib—Pruritus—Ramipril—type 2 diabetes mellitus	6.62e-05	0.000364	CcSEcCtD
Bosutinib—ABCB1—islet of Langerhans—type 2 diabetes mellitus	6.53e-05	0.000529	CbGeAlD
Bosutinib—CYP3A4—kidney—type 2 diabetes mellitus	6.53e-05	0.000529	CbGeAlD
Bosutinib—Nausea—Losartan—type 2 diabetes mellitus	6.49e-05	0.000357	CcSEcCtD
Bosutinib—Diarrhoea—Ramipril—type 2 diabetes mellitus	6.41e-05	0.000352	CcSEcCtD
Bosutinib—Dizziness—Ramipril—type 2 diabetes mellitus	6.19e-05	0.000341	CcSEcCtD
Bosutinib—Vomiting—Ramipril—type 2 diabetes mellitus	5.95e-05	0.000328	CcSEcCtD
Bosutinib—Rash—Ramipril—type 2 diabetes mellitus	5.9e-05	0.000325	CcSEcCtD
Bosutinib—Dermatitis—Ramipril—type 2 diabetes mellitus	5.9e-05	0.000325	CcSEcCtD
Bosutinib—Headache—Ramipril—type 2 diabetes mellitus	5.87e-05	0.000323	CcSEcCtD
Bosutinib—ABCB1—retina—type 2 diabetes mellitus	5.58e-05	0.000452	CbGeAlD
Bosutinib—Nausea—Ramipril—type 2 diabetes mellitus	5.56e-05	0.000306	CcSEcCtD
Bosutinib—ABCB1—nephron tubule—type 2 diabetes mellitus	5.26e-05	0.000426	CbGeAlD
Bosutinib—ABCB1—cardiovascular system—type 2 diabetes mellitus	4.72e-05	0.000383	CbGeAlD
Bosutinib—ABCB1—kidney—type 2 diabetes mellitus	4.62e-05	0.000374	CbGeAlD
Bosutinib—ABCB1—pancreas—type 2 diabetes mellitus	4.59e-05	0.000372	CbGeAlD
Bosutinib—ABCB1—cortex of kidney—type 2 diabetes mellitus	4.5e-05	0.000365	CbGeAlD
Bosutinib—ABCB1—adipose tissue—type 2 diabetes mellitus	4.16e-05	0.000338	CbGeAlD
Bosutinib—CYP3A4—liver—type 2 diabetes mellitus	4.13e-05	0.000334	CbGeAlD
Bosutinib—ABCB1—liver—type 2 diabetes mellitus	2.92e-05	0.000237	CbGeAlD
Bosutinib—CYP3A4—Metabolism—GLP1R—type 2 diabetes mellitus	6.5e-07	2.98e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—TGFB1—type 2 diabetes mellitus	6.49e-07	2.97e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—IL6—type 2 diabetes mellitus	6.48e-07	2.97e-06	CbGpPWpGaD
Bosutinib—CSNK1E—Signaling Pathways—AKT1—type 2 diabetes mellitus	6.47e-07	2.96e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—RELA—type 2 diabetes mellitus	6.47e-07	2.96e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CCL2—type 2 diabetes mellitus	6.46e-07	2.96e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	6.43e-07	2.95e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PRKCB—type 2 diabetes mellitus	6.41e-07	2.94e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—EGFR—type 2 diabetes mellitus	6.4e-07	2.93e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—EGFR—type 2 diabetes mellitus	6.37e-07	2.91e-06	CbGpPWpGaD
Bosutinib—IRAK1—Immune System—AKT1—type 2 diabetes mellitus	6.35e-07	2.91e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IGF1—type 2 diabetes mellitus	6.35e-07	2.91e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—AKT2—type 2 diabetes mellitus	6.34e-07	2.9e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.31e-07	2.89e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—SRC—type 2 diabetes mellitus	6.31e-07	2.89e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—GNB3—type 2 diabetes mellitus	6.31e-07	2.89e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PPARGC1A—type 2 diabetes mellitus	6.31e-07	2.89e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—HMOX1—type 2 diabetes mellitus	6.28e-07	2.87e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—NFKB1—type 2 diabetes mellitus	6.26e-07	2.86e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	6.26e-07	2.86e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—CASP3—type 2 diabetes mellitus	6.24e-07	2.86e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	6.23e-07	2.85e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—SRC—type 2 diabetes mellitus	6.22e-07	2.85e-06	CbGpPWpGaD
Bosutinib—SRC—Innate Immune System—AKT1—type 2 diabetes mellitus	6.22e-07	2.85e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—IL6—type 2 diabetes mellitus	6.2e-07	2.84e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CAT—type 2 diabetes mellitus	6.19e-07	2.84e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.19e-07	2.83e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—EGFR—type 2 diabetes mellitus	6.11e-07	2.8e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—CASP3—type 2 diabetes mellitus	6.09e-07	2.79e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—SRC—type 2 diabetes mellitus	6.08e-07	2.78e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SLC2A2—type 2 diabetes mellitus	6.07e-07	2.78e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IRS1—type 2 diabetes mellitus	6.07e-07	2.78e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—IL6—type 2 diabetes mellitus	6.06e-07	2.78e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—VEGFA—type 2 diabetes mellitus	6.06e-07	2.77e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	6.03e-07	2.76e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—APOB—type 2 diabetes mellitus	6.01e-07	2.75e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Immune System—AKT1—type 2 diabetes mellitus	5.98e-07	2.74e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—IL6—type 2 diabetes mellitus	5.98e-07	2.74e-06	CbGpPWpGaD
Bosutinib—SRC—Adaptive Immune System—AKT1—type 2 diabetes mellitus	5.97e-07	2.73e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.97e-07	2.73e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.97e-07	2.73e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.96e-07	2.73e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—MTR—type 2 diabetes mellitus	5.95e-07	2.72e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CPT1A—type 2 diabetes mellitus	5.95e-07	2.72e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.91e-07	2.7e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.9e-07	2.7e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.87e-07	2.69e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—GSTM1—type 2 diabetes mellitus	5.85e-07	2.68e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.84e-07	2.67e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.83e-07	2.67e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NAMPT—type 2 diabetes mellitus	5.83e-07	2.67e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—INS—type 2 diabetes mellitus	5.81e-07	2.66e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.8e-07	2.66e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—HBA1—type 2 diabetes mellitus	5.8e-07	2.65e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—LIPC—type 2 diabetes mellitus	5.8e-07	2.65e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GCK—type 2 diabetes mellitus	5.8e-07	2.65e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—EGFR—type 2 diabetes mellitus	5.79e-07	2.65e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—EGFR—type 2 diabetes mellitus	5.77e-07	2.64e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP11A1—type 2 diabetes mellitus	5.76e-07	2.64e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—IL6—type 2 diabetes mellitus	5.76e-07	2.64e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.76e-07	2.64e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.76e-07	2.64e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.75e-07	2.63e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—LPL—type 2 diabetes mellitus	5.74e-07	2.63e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling by GPCR—AKT1—type 2 diabetes mellitus	5.72e-07	2.62e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CCL2—type 2 diabetes mellitus	5.72e-07	2.62e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.69e-07	2.61e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—IL6—type 2 diabetes mellitus	5.66e-07	2.59e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SLC9A1—type 2 diabetes mellitus	5.66e-07	2.59e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—TGFB1—type 2 diabetes mellitus	5.64e-07	2.58e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.63e-07	2.58e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—RELA—type 2 diabetes mellitus	5.62e-07	2.57e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—ADCY5—type 2 diabetes mellitus	5.62e-07	2.57e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IGF1—type 2 diabetes mellitus	5.62e-07	2.57e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AKT2—type 2 diabetes mellitus	5.62e-07	2.57e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—GPX1—type 2 diabetes mellitus	5.6e-07	2.56e-06	CbGpPWpGaD
Bosutinib—ERBB4—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.59e-07	2.56e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CETP—type 2 diabetes mellitus	5.59e-07	2.56e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.57e-07	2.55e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—TGFB1—type 2 diabetes mellitus	5.56e-07	2.55e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.55e-07	2.54e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—IL6—type 2 diabetes mellitus	5.55e-07	2.54e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—IL6—type 2 diabetes mellitus	5.55e-07	2.54e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—IL6—type 2 diabetes mellitus	5.53e-07	2.53e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—MMP9—type 2 diabetes mellitus	5.52e-07	2.53e-06	CbGpPWpGaD
Bosutinib—PTK2B—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.51e-07	2.52e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.49e-07	2.51e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—NFKB1—type 2 diabetes mellitus	5.46e-07	2.5e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CD36—type 2 diabetes mellitus	5.45e-07	2.5e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—EGFR—type 2 diabetes mellitus	5.45e-07	2.5e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—SRC—type 2 diabetes mellitus	5.44e-07	2.49e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—TGFB1—type 2 diabetes mellitus	5.43e-07	2.49e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—RELA—type 2 diabetes mellitus	5.42e-07	2.48e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—IL6—type 2 diabetes mellitus	5.41e-07	2.48e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PPP2CA—type 2 diabetes mellitus	5.39e-07	2.47e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—IL6—type 2 diabetes mellitus	5.39e-07	2.47e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling by GPCR—AKT1—type 2 diabetes mellitus	5.35e-07	2.45e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—IL6—type 2 diabetes mellitus	5.35e-07	2.45e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—SERPINE1—type 2 diabetes mellitus	5.34e-07	2.44e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—EGFR—type 2 diabetes mellitus	5.33e-07	2.44e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—IL6—type 2 diabetes mellitus	5.33e-07	2.44e-06	CbGpPWpGaD
Bosutinib—ROCK1—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.31e-07	2.43e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—SRC—type 2 diabetes mellitus	5.31e-07	2.43e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—IL6—type 2 diabetes mellitus	5.3e-07	2.43e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.29e-07	2.42e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—IL6—type 2 diabetes mellitus	5.23e-07	2.39e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Immune System—AKT1—type 2 diabetes mellitus	5.23e-07	2.39e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SNAP25—type 2 diabetes mellitus	5.2e-07	2.38e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PSMD6—type 2 diabetes mellitus	5.2e-07	2.38e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SREBF1—type 2 diabetes mellitus	5.2e-07	2.38e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—SRC—type 2 diabetes mellitus	5.19e-07	2.38e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—MTHFR—type 2 diabetes mellitus	5.17e-07	2.37e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.17e-07	2.37e-06	CbGpPWpGaD
Bosutinib—RPS6KB1—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.12e-07	2.34e-06	CbGpPWpGaD
Bosutinib—MAP2K5—Signaling Pathways—AKT1—type 2 diabetes mellitus	5.12e-07	2.34e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—SRC—type 2 diabetes mellitus	5.11e-07	2.34e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—EGFR—type 2 diabetes mellitus	5.11e-07	2.34e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—IL6—type 2 diabetes mellitus	5.1e-07	2.34e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CTGF—type 2 diabetes mellitus	5.1e-07	2.34e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Immune System—AKT1—type 2 diabetes mellitus	5.1e-07	2.33e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NOS3—type 2 diabetes mellitus	5.1e-07	2.33e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—PIK3R1—type 2 diabetes mellitus	5.1e-07	2.33e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—SRC—type 2 diabetes mellitus	5.09e-07	2.33e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PPARA—type 2 diabetes mellitus	5.07e-07	2.32e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—CASP3—type 2 diabetes mellitus	5.07e-07	2.32e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—VEGFA—type 2 diabetes mellitus	5.06e-07	2.32e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—HMGCR—type 2 diabetes mellitus	5.06e-07	2.32e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—IL6—type 2 diabetes mellitus	5.04e-07	2.31e-06	CbGpPWpGaD
Bosutinib—LYN—Immune System—AKT1—type 2 diabetes mellitus	4.99e-07	2.29e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.98e-07	2.28e-06	CbGpPWpGaD
Bosutinib—ABL1—Immune System—AKT1—type 2 diabetes mellitus	4.97e-07	2.28e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.95e-07	2.27e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ADRA2A—type 2 diabetes mellitus	4.95e-07	2.27e-06	CbGpPWpGaD
Bosutinib—ERBB3—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.93e-07	2.26e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—IL6—type 2 diabetes mellitus	4.92e-07	2.25e-06	CbGpPWpGaD
Bosutinib—FYN—Immune System—AKT1—type 2 diabetes mellitus	4.92e-07	2.25e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—AGT—type 2 diabetes mellitus	4.91e-07	2.25e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—IL6—type 2 diabetes mellitus	4.89e-07	2.24e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Immune System—AKT1—type 2 diabetes mellitus	4.89e-07	2.24e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.89e-07	2.24e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.86e-07	2.23e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—CALM1—type 2 diabetes mellitus	4.83e-07	2.21e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Disease—AKT1—type 2 diabetes mellitus	4.82e-07	2.21e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—APOE—type 2 diabetes mellitus	4.81e-07	2.2e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—TGFB1—type 2 diabetes mellitus	4.81e-07	2.2e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—RELA—type 2 diabetes mellitus	4.8e-07	2.2e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.79e-07	2.19e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.76e-07	2.18e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—IL6—type 2 diabetes mellitus	4.76e-07	2.18e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—APOA1—type 2 diabetes mellitus	4.76e-07	2.18e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP2E1—type 2 diabetes mellitus	4.75e-07	2.18e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.74e-07	2.17e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.74e-07	2.17e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—EGFR—type 2 diabetes mellitus	4.72e-07	2.16e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Disease—AKT1—type 2 diabetes mellitus	4.71e-07	2.16e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SLC2A1—type 2 diabetes mellitus	4.7e-07	2.15e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CYP1A2—type 2 diabetes mellitus	4.7e-07	2.15e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—IL6—type 2 diabetes mellitus	4.69e-07	2.15e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.65e-07	2.13e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling by GPCR—AKT1—type 2 diabetes mellitus	4.65e-07	2.13e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.64e-07	2.13e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.62e-07	2.11e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—IL6—type 2 diabetes mellitus	4.6e-07	2.11e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.57e-07	2.09e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.57e-07	2.09e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.55e-07	2.08e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—TGFB1—type 2 diabetes mellitus	4.55e-07	2.08e-06	CbGpPWpGaD
Bosutinib—FYN—Disease—AKT1—type 2 diabetes mellitus	4.54e-07	2.08e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Disease—AKT1—type 2 diabetes mellitus	4.51e-07	2.07e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—SLC2A4—type 2 diabetes mellitus	4.51e-07	2.06e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GCG—type 2 diabetes mellitus	4.51e-07	2.06e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.48e-07	2.05e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—EGFR—type 2 diabetes mellitus	4.46e-07	2.04e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—IL6—type 2 diabetes mellitus	4.45e-07	2.04e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—IL6—type 2 diabetes mellitus	4.44e-07	2.03e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—SRC—type 2 diabetes mellitus	4.42e-07	2.02e-06	CbGpPWpGaD
Bosutinib—PTK2—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.39e-07	2.01e-06	CbGpPWpGaD
Bosutinib—YES1—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.33e-07	1.98e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—CASP3—type 2 diabetes mellitus	4.33e-07	1.98e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.3e-07	1.97e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—SRC—type 2 diabetes mellitus	4.26e-07	1.95e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—IL6—type 2 diabetes mellitus	4.25e-07	1.95e-06	CbGpPWpGaD
Bosutinib—EGFR—Immune System—AKT1—type 2 diabetes mellitus	4.25e-07	1.94e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PPARG—type 2 diabetes mellitus	4.19e-07	1.92e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—IL6—type 2 diabetes mellitus	4.19e-07	1.92e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—VEGFA—type 2 diabetes mellitus	4.15e-07	1.9e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—INS—type 2 diabetes mellitus	4.11e-07	1.88e-06	CbGpPWpGaD
Bosutinib—IRAK1—Signaling Pathways—AKT1—type 2 diabetes mellitus	4.11e-07	1.88e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—IL6—type 2 diabetes mellitus	4.1e-07	1.88e-06	CbGpPWpGaD
Bosutinib—LCK—Immune System—AKT1—type 2 diabetes mellitus	4.09e-07	1.87e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—MMP9—type 2 diabetes mellitus	4.09e-07	1.87e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—NFKB1—type 2 diabetes mellitus	4.04e-07	1.85e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.95e-07	1.81e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—IL6—type 2 diabetes mellitus	3.93e-07	1.8e-06	CbGpPWpGaD
Bosutinib—EGFR—Disease—AKT1—type 2 diabetes mellitus	3.92e-07	1.79e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PPARGC1A—type 2 diabetes mellitus	3.88e-07	1.78e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GNB3—type 2 diabetes mellitus	3.88e-07	1.78e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—HMOX1—type 2 diabetes mellitus	3.87e-07	1.77e-06	CbGpPWpGaD
Bosutinib—MAP3K7—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.87e-07	1.77e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CAT—type 2 diabetes mellitus	3.82e-07	1.75e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.81e-07	1.74e-06	CbGpPWpGaD
Bosutinib—LCK—Disease—AKT1—type 2 diabetes mellitus	3.78e-07	1.73e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—ALB—type 2 diabetes mellitus	3.77e-07	1.73e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.73e-07	1.71e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—APOB—type 2 diabetes mellitus	3.7e-07	1.7e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—VEGFA—type 2 diabetes mellitus	3.67e-07	1.68e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—IL6—type 2 diabetes mellitus	3.66e-07	1.68e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—IL6—type 2 diabetes mellitus	3.63e-07	1.66e-06	CbGpPWpGaD
Bosutinib—SRC—Immune System—AKT1—type 2 diabetes mellitus	3.62e-07	1.66e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PIK3R1—type 2 diabetes mellitus	3.61e-07	1.65e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—NOS3—type 2 diabetes mellitus	3.61e-07	1.65e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GSTM1—type 2 diabetes mellitus	3.6e-07	1.65e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—IL6—type 2 diabetes mellitus	3.57e-07	1.64e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—LPL—type 2 diabetes mellitus	3.54e-07	1.62e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—IL6—type 2 diabetes mellitus	3.5e-07	1.6e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ADCY5—type 2 diabetes mellitus	3.46e-07	1.59e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—GPX1—type 2 diabetes mellitus	3.45e-07	1.58e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—IL6—type 2 diabetes mellitus	3.44e-07	1.58e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—IL6—type 2 diabetes mellitus	3.43e-07	1.57e-06	CbGpPWpGaD
Bosutinib—MAP2K2—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.38e-07	1.55e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—TGFB1—type 2 diabetes mellitus	3.37e-07	1.54e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CD36—type 2 diabetes mellitus	3.36e-07	1.54e-06	CbGpPWpGaD
Bosutinib—SRC—Disease—AKT1—type 2 diabetes mellitus	3.34e-07	1.53e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PPP2CA—type 2 diabetes mellitus	3.32e-07	1.52e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—EGFR—type 2 diabetes mellitus	3.3e-07	1.51e-06	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—PTGS2—type 2 diabetes mellitus	3.3e-07	1.51e-06	CbGpPWpGaD
Bosutinib—PDGFRB—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.3e-07	1.51e-06	CbGpPWpGaD
Bosutinib—LYN—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.23e-07	1.48e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—MTHFR—type 2 diabetes mellitus	3.18e-07	1.46e-06	CbGpPWpGaD
Bosutinib—FYN—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.18e-07	1.45e-06	CbGpPWpGaD
Bosutinib—MAP2K1—Signaling Pathways—AKT1—type 2 diabetes mellitus	3.16e-07	1.45e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PPARA—type 2 diabetes mellitus	3.12e-07	1.43e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AGT—type 2 diabetes mellitus	3.03e-07	1.39e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—IL6—type 2 diabetes mellitus	2.98e-07	1.36e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—CALM1—type 2 diabetes mellitus	2.98e-07	1.36e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—APOE—type 2 diabetes mellitus	2.96e-07	1.36e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—APOA1—type 2 diabetes mellitus	2.93e-07	1.34e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—IL6—type 2 diabetes mellitus	2.87e-07	1.31e-06	CbGpPWpGaD
Bosutinib—EGFR—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.75e-07	1.26e-06	CbGpPWpGaD
Bosutinib—LCK—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.65e-07	1.21e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PPARG—type 2 diabetes mellitus	2.58e-07	1.18e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—IL6—type 2 diabetes mellitus	2.54e-07	1.16e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—INS—type 2 diabetes mellitus	2.53e-07	1.16e-06	CbGpPWpGaD
Bosutinib—SRC—Signaling Pathways—AKT1—type 2 diabetes mellitus	2.34e-07	1.07e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—ALB—type 2 diabetes mellitus	2.32e-07	1.06e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PIK3R1—type 2 diabetes mellitus	2.22e-07	1.02e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—NOS3—type 2 diabetes mellitus	2.22e-07	1.02e-06	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—PTGS2—type 2 diabetes mellitus	2.03e-07	9.3e-07	CbGpPWpGaD
Bosutinib—ABCB1—Metabolism—AKT1—type 2 diabetes mellitus	1.66e-07	7.59e-07	CbGpPWpGaD
Bosutinib—CYP3A4—Metabolism—AKT1—type 2 diabetes mellitus	1.02e-07	4.67e-07	CbGpPWpGaD
